Rallybio (RLYB) Amortizatization of Intangibles (2022 - 2026)
Rallybio (RLYB) posted Amortizatization of Intangibles of -$51000.0 for Q1 2026, up 47.42% sequentially from -$97000.0 in Q4 2025, and up 75.71% YoY from -$29024.4 in Q1 2025.
Rallybio (RLYB) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Rallybio has reported Amortizatization of Intangibles for 5 years, with the latest figure at -$51000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 75.71% year-over-year to -$51000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$414000.0 (up 67.73% YoY) and the FY2025 annual result came in at -$573000.0, up 64.45% from the prior year.
- Amortizatization of Intangibles grew to -$51000.0 in Q1 2026 per RLYB's latest filing, from -$97000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $73000.0 in Q2 2022 and troughed at -$895000.0 in Q1 2023.
- A 5-year average of -$338823.5 and a median of -$316000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2026: Amortizatization of Intangibles slumped 2586.11% in 2023, then jumped 75.71% in 2026.
- Over 5 years, Amortizatization of Intangibles stood at -$462000.0 in 2022, then sank by 42.21% to -$657000.0 in 2023, then soared by 51.9% to -$316000.0 in 2024, then surged by 69.3% to -$97000.0 in 2025, then soared by 47.42% to -$51000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$51000.0, -$97000.0, and -$113000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | -5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,000.00 |
| Jun 30, 2026 | -5,000.00 |
| Mar 31, 2026 | -51,000.00 |
| Mar 31, 2026 | -51,000.00 |
| Dec 31, 2025 | -97,000.00 |
| Dec 31, 2025 | -97,000.00 |
| Sep 30, 2025 | -113,000.00 |
| Sep 30, 2025 | -113,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Mar 31, 2025 | -210,000.00 |
| Mar 31, 2025 | -210,000.00 |
| Dec 31, 2024 | -316,000.00 |
| Dec 31, 2024 | -316,000.00 |
| Sep 30, 2024 | -341,000.00 |
| Sep 30, 2024 | -341,000.00 |
| Jun 30, 2024 | -416,000.00 |
| Jun 30, 2024 | -416,000.00 |
| Mar 31, 2024 | -539,000.00 |
| Mar 31, 2024 | -539,000.00 |